Docstoc

Kendall Law Group Investigates Valeant Pharmaceuticals International Merger for Shareholders

Document Sample
Kendall Law Group Investigates Valeant Pharmaceuticals International Merger for Shareholders Powered By Docstoc
					Kendall Law Group Investigates Valeant
Pharmaceuticals International Merger for
Shareholders
June 22, 2010 12:46 PM Eastern Daylight Time  

DALLAS--(EON: Enhanced Online News)--Kendall Law Group, a national securities firm led by a former federal
judge and a former U.S. Attorney, is investigating Valeant Pharmaceuticals International (NYSE: VRX) for
shareholders in connection with the proposed merger with Biovail. The firm’s investigation seeks to determine
whether Valeant and its Board breached their fiduciary duties by entering into the agreement without properly
shopping for a deal that would provide better value for shareholders. If you are a Valeant shareholder and would like
additional information about your rights, contact the Kendall Law Group at 877-744-3728 or by email at
jmckey@kendalllawgroup.com.

On June 21, 2010, the companies announced that they had entered into an agreement for Valeant to be acquired by
Biovail in a transaction valued at approximately $3.2 billion. Under the terms of the agreement, Valeant shareholders
will receive a cash dividend of $16.77 per share and 1.7809 shares of Biovail common stock for each share of
Valeant stock held. Based on Biovail’s closing price of $14.60 the day before the deal was announced, this offer
values Valeant stock at $42.77 per share. Because Valeant shares closed at $45.87 on Friday, the firm believes this
offer to be inadequate for the shareholders.

Kendall Law Group was founded by a former federal judge, includes a former United States Attorney, prosecutors
and securities lawyers who are experienced in complex securities litigation. The firm has been counsel in numerous
merger and acquisition cases nationwide, including some of the largest transactions in the United States. Since leaving
the bench to return to trial work, Mr. Kendall has had tremendous success at the prosecution of patent, consumer
and securities class action litigation either as lead, co-lead or liaison counsel.

Contacts
Kendall Law Group LLP
Jamie McKey, 214-744-3000
Toll Free: 877-744-3728
Facsimile: 214-744-3015
jmckey@kendalllawgroup.com
www.kendalllawgroup.com

Permalink: http://eon.businesswire.com/news/eon/20100622006806/en/Biovail/Kendall-Law-Group/NYSE%3A-
VRX

				
DOCUMENT INFO
Shared By:
Tags:
Stats:
views:5
posted:6/22/2010
language:English
pages:1
Description: DALLAS--(EON: Enhanced Online News)--(DALLAS) Kendall Law Group, a national securities firm led by a former federal judge and a former U.S. Attorney, is investigating Valeant Pharmaceuticals International (NYSE: VRX) for shareholders img border='0' title='Add to Google' alt='Add to Google' src='http://imag
EON: Enhanced Online News EON: Enhanced Online News http://eon.businesswire.com
About At EON: Enhanced Online News, we show you how to make your online press release thrive. If you want to drive traffic to your website, generate sales leads, make an announcement, or promote a new product, EON: Enhanced Online News delivers the online visibility that you need. EON: Enhanced Online News powered by Business Wire.